Meeting
2013 ASCO Annual Meeting
Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.
Authors
Daniel Virgil Thomas Catenacci
University of Chicago, Chicago, IL
Daniel Virgil Thomas Catenacci , Nathan Bahary , Sreenivasa R. Nattam , Robert de Wilton Marsh , James Alfred Wallace , Lakshmi Rajdev , Deirdre Jill Cohen , Bethany G. Sleckman , Heinz-Josef Lenz , Patrick J. Stiff , Sachdev P. Thomas , Peng Xu , Les Henderson , Margit Naomi Horiba , Michael Vannier , Theodore Karrison , Walter Michael Stadler , Hedy Lee Kindler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT01064622
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4012)
DOI
10.1200/jco.2013.31.15_suppl.4012
Abstract #
4012
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).
First Author: Ana De Jesus-Acosta
Poster
2015 ASCO Annual Meeting
SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer.
First Author: Vincent M. Chung
Poster
2015 Gastrointestinal Cancers Symposium
Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.
First Author: Eric Van Cutsem
Poster
2015 Gastrointestinal Cancers Symposium
Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).
First Author: Edward Samuel James